Document:

infy-ex412_7.htm

Exhibit 4.12

 

OVERVIEW OF EXECUTIVE LEADERSHIP COMPENSATION

	
 
	
1.
	
Executive Leadership Compensation at Infosys

 

Our Executive Leadership Compensation follows the concept of Total Rewards which comprise three primary components of Base/Fixed Pay, Performance Bonus and Stock Incentives, where a significant portion of rewards are in the form of stock incentives, in order to align with interest of the shareholders.

 

Executive Leadership (also called “Executives”) are the Chief Executive Officer (CEO), Chief Operating Officer (COO), Chief Financial Officer (CFO), Presidents, Group General Counsel & Chief Compliance Officer and Group Head- HRD and are named below.

 

 

		
	
Executive
	
Position

	
Mr. Salil Parekh
	
Chief Executive Officer and Managing Director

	
Mr. U.B. Pravin Rao
	
Chief Operating Officer and Whole-time Director

	
Mr. Nilanjan Roy
	
Chief Financial Officer

	
Mr. Ravi Kumar S.
	
President and Deputy Chief Operating Officer

	
Mr. Mohit Joshi
	
President

	
Ms. Inderpreet Sawhney
	
Group General Counsel & Chief Compliance Officer

	
Mr. Krishnamurthy Shankar
	
Group Head – Human Resources and Infosys Leadership Institute

 

	
 
	
2.
	
Nomination and Remuneration Committee of the Board

 

The Nomination and Remuneration Committee of the Board (henceforth referred to as NRC) acts on behalf of the Board on matters relating to the compensation of Directors and other Executives. It makes recommendations for changes to the compensation structure, and within the limits approved by the shareholders, as may be applicable.

 

The shareholders approve the overall compensation structure for all whole-time directors.

 

	
 
	
3.
	
Key Aspects of Executive Compensation Policy

 

	
 
	
a.
	
Key Objectives:

 

The Company’s executive pay programs support our Executive Compensation philosophy which aims to:

 

	
 
	
•
	
Attract and retain the best executive talent in order to achieve superior results;

 

	

	
Overview of Executive Leadership Compensation   
	
    1    

 

	
 
		

	
 
	
•
	
Create a performance-oriented culture by rewarding performance on comprehensive goals, which include financial, strategic and operational goals; and
	
 

	
 
	
•
	
Emphasize sustainable, long-term shareholder value creation through allocation of performance- oriented stock-based incentives.
	
 

 

 

	
 
	
b.
	
Primary Pay Components of the Executives’ Compensation

 

In support of the above key objectives, the Company’s Executive pay program has been designed around three primary pay components: Base/Fixed Pay, Performance Bonus and Stock Incentives. These three components together constitute the “Total Rewards” of the Executive.

 

	
 
	
•
	
Base/Fixed pay: The fixed cash component is guaranteed pay and paid periodically.

	
 
	
•
	
Performance Bonus: Cash bonus is payable on the achievement of KPIs as established by the NRC. The Company operates a non-contractual discretionary Performance Bonus Plan.

	
 
	
•
	
Stock Incentives: Stock or Equity based incentives are a substantial part of the Total Rewards of Executives and are determined by the desired pay mix standards for that level. Stocks incentives can be granted as part of Total Rewards or over and above, as decided by CEO, COO and NRC from time to time. The stock incentives are governed by the 2015 Stock Incentive Compensation Plan (2015 Plan), the Expanded Stock Ownership Program (2019 Plan) or such other plans as may be approved by the shareholders from time to time. Occasionally, the NRC may approve a special or one-time stock based incentives to be granted or vested on the achievement of extraordinary performance goals. One-time equity grants may also be issued to new hires in Executive roles, to meet specific compensation expectations, and these grants may be with special vesting conditions.
	
 

 

	
 
	
c.
	
Executive Compensation Fitment and Benchmarking

 

Executive compensation at Infosys is generally aimed towards meeting the market median of total compensation benchmarked amongst the chosen peer group, adjusted as needed to reflect considerations for internal equity, consistency and overall affordability.

 

For Executives, pay at risk in the form of stock incentives and performance bonus together constitute about 65% to 85% of their compensation. 

 

	
 
	
d.
	
Compensation Practices

 

The highlights of our current compensation practices for our Executives are as below:

 

	
 
	
•
	
Use appropriate peer groups when establishing the total rewards benchmarks for a particular Executive role

	
 
	
•
	
Align Executive pay with shareholder value through performance-based Stock incentives

	
 
	
•
	
Retain Executives through multi-year vesting of Stock Incentives

 

 

	

	
Overview of Executive Leadership Compensation   
	
    2    

 

 

	
 
	
e.
	
Pay for Performance

 

Consistent with the Company’s Executive Compensation philosophy, a significant portion of Executives’ pay is performance-based and ‘at-risk’.

 

	
 
	
i.
	
Performance Bonus

 

The Executive’s performance bonus is linked to the achievement of Company goals like revenue growth, operating margin along with components of individual goals as applicable, linked to the Company’s business targets. The goals and the final payout rates are reviewed and approved by the NRC.

 

	
 
	
ii.
	
Stock Incentives

 

All Stock or Equity based incentives are generally granted or vested based on achievement against Company and/or Individual performance parameters. Time based Equity grants are generally dependent upon the achievement of Company and individual performance. This is further indexed to the Company stock grant budget pool derived from the Company’s overall performance and affordability and can be adjusted for individual performance. Stock incentives may not be granted if the Company’s performance is below a specific threshold, as determined by the NRC from time to time. In case of Performance based Equity grants, the numbers of shares that will vest is based Company’s and/or individuals’ achievement of certain performance parameters. 

 

 

	
 
	
f.
	
Additional Executive Compensation practices and Employment agreements

 

In addition to the primary pay components, the Company provides competitive health and wellness benefits and perquisites. These benefits are designed to protect the financial, physical and emotional well- being of employees and allow them to plan for their own retirement. In general, these benefits do not constitute a significant portion of Executive compensation.

 

NRC aims to ensure that the Company’s interests are protected through appropriate executive obligations including non-disclosure, non-compete and non-solicitation agreements. Further, the Company has adopted a recoupment policy under which any incentive compensation paid or payable to Executives (including any bonus pay and equity awards) will be subject to forfeiture, cancellation, recoupment or clawback in accordance with the applicable laws, government regulations and stock exchange requirements.

 

With respect to the employment agreement with our Executive Directors, the current agreement of Mr. Salil Parekh including the addendum to CEO Employment Contract and the agreement of Mr. U. B. Pravin Rao including the addendum to COO Employment Contract can be accessed at www.infosys.com

 

“The details of compensation for the Executives for the relative fiscal year is available in the Annual report.”

 

	

	
Overview of Executive Leadership Compensation   
	
    3Exhibit 4.4

 

THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY
TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

WARRANT
TO PURCHASE COMMON STOCK

 

	Corporation:

    Number
    of Shares:

    Class
    of Stock:

    Initial
    Exercise Price:

    Issue
    Date:

    Expiration:
	Sera
    Prognostics, Inc., a Delaware corporation

    [__]

    Common
    Stock, $0.0001 par value per share

    $9.99
    per share

    [__],
    2021

    [__],
    2026

 

THIS
WARRANT CERTIFIES THAT, for good and valuable consideration, the receipt of which is hereby acknowledged, [__]
or its assignee or transferee (“Holder”) is entitled to purchase the number of fully paid and nonassessable
shares of Common Stock, $0.0001 par value per share (the “Shares”) of Sera Prognostics, Inc. (the “Company”)
at the initial exercise price per Share (the “Warrant Price”) all as set forth above and as adjusted pursuant
to Article 2 of this warrant, subject to the provisions and upon the terms and conditions set forth in this warrant.

 

ARTICLE
1

EXERCISE

 

1.1             Method
of Exercise. Holder may exercise this warrant by delivering this
warrant, a duly executed Notice of Exercise in substantially the form attached as Appendix 1, and a duly executed Joinder to the Fourth
Amended and Restated Investors’ Rights Agreement, dated as of February 23, 2021, between the Company and certain stockholders of
the Company (as amended from time to time, the “Investors’ Rights Agreement”), and the Fourth Amended and Restated
Voting Agreement, dated as of February 23, 2021, between the Company and certain stockholders of the Company (as amended from time to
time, the “Voting Agreement”), in substantially the form attached as Appendix 2 to the principal office of the Company.
Unless Holder is exercising the conversion right set forth in Section 1.2, Holder shall also deliver to the Company a check for the aggregate
Warrant Price for the Shares being purchased.

 

1.2             Conversion
Right. In lieu of exercising this warrant as specified in Section
1.1, Holder may from time to time convert this warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate
fair market value of the Shares or other securities otherwise issuable upon exercise of this warrant minus the aggregate Warrant Price
of such Shares by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Section
1.3.

 

     

     

    

 

1.3             Fair
Market Value. If the Shares are traded regularly in a public market,
the fair market value of the Shares shall be the closing price of the Shares reported for the business day immediately before Holder
delivers its Notice of Exercise to the Company. If the Shares are not regularly traded in a public market, the Board of Directors of
the Company and the Holder shall jointly determine fair market value in their collective reasonable good faith judgment; provided,
that if the Board of Directors of the Company and the Holder are unable to agree on the fair market value per share of the Shares within
a reasonable period of time (not to exceed twenty days from the Company’s receipt of the Notice of Exercise), such fair market
value shall be determined by a nationally recognized investment banking, accounting or valuation firm jointly selected by the Board of
Directors of the Company and the Holder. The determination of such firm shall be final and conclusive, and the fees and expenses of such
firm shall be borne equally by the Company and the Holder. In determining the Fair Market Value of the Shares, an orderly sale transaction
between a willing buyer and a willing seller shall be assumed, using valuation techniques then prevailing in the securities industry
without regard to the lack of liquidity of the Shares due to any restrictions (contractual or otherwise) applicable thereto or any discount
for minority interests and assuming full disclosure of all relevant information and a reasonable period of time for effectuating such
sale and assuming the sale of all of the issued and outstanding Common Stock (including fractional interests) calculated on a fully diluted
basis to include the conversion or exchange of all securities then outstanding that are convertible into or exchangeable for Common Stock
and the exercise of all rights and warrants then outstanding and exercisable to purchase shares of Common Stock or securities convertible
into or exchangeable for shares of Common Stock; provided, that such assumption shall not include those securities, rights and
warrants (a) owned or held by or for the account of the Company or any of its subsidiaries, or (b) convertible or exchangeable into Common
Stock where the conversion, exchange or exercise price per share is greater than the Fair Market Value.

 

1.4             Delivery
of Certificate and New Warrant. Promptly after Holder exercises or
converts this warrant, the Company shall deliver to Holder certificates for the Shares acquired and, if this warrant has not been fully
exercised or converted and has not expired, a new warrant representing the Shares not so acquired.

 

1.5             Replacement
of Warrants. On receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this warrant and, in the case of loss, theft or destruction, on delivery of
an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender
and cancellation of this warrant, the Company at its expense shall execute and deliver, in lieu of this warrant, a new warrant of like
tenor.

 

1.6             Treatment
of Warrant Upon Acquisition of the Company.

 

1.6.1        “Acquisition.”
For the purpose of this warrant, “Acquisition” means (a) merger or consolidation of the Company into or with another entity,
or a plan of exchange between the Company and any other entity, or the merger or consolidation of any other entity into or with the Company
(except for a merger, consolidation or exchange in which the holders of the voting power of the capital stock of the Company immediately
prior to such merger, consolidation or exchange continue to hold at least 50% of the voting power of the capital stock of the Company
or the surviving or acquiring entity), (b) sale, lease, exclusive license or other disposition of all or substantially all of the assets
of the Company, or (c) the acquisition of ownership by any Person or group of more than 50% of the Company’s voting stock.

 

    2

     

    

 

1.6.2        Exercise
Upon Acquisition. Upon the closing of any Acquisition in which the
consideration to be received by the Company’s stockholders consists of cash, marketable securities, or a combination of both cash
and marketable securities, this warrant shall be deemed to have been automatically converted pursuant to Section 1.2, and thereafter
Holder shall participate in the Acquisition on the same terms as other holders of the same class of securities of the Company.

 

1.6.3        Assumption
of Warrant. The Company shall not effect any Acquisition not referred
to in Section 1.6.2 unless, prior to the consummation thereof, the successor person or entity (if other than the Company) resulting from
such transaction, shall assume, by written instrument satisfactory to the Holder, the obligations of this warrant, upon which this warrant
shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise
of the unexercised portion of this warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to
further adjustment from time to time in accordance with the provisions of this warrant. Alternatively (and notwithstanding anything to
the contrary herein), with respect to any Acquisition, Holder shall have the right to elect prior to the consummation thereof, to give
effect to the exercise rights contained in Section 1.1 or the conversion rights contained in Section 1.2.

 

ARTICLE
2

ADJUSTMENTS TO THE SHARES

 

2.1            Stock
Dividends, Splits, Etc. If the Company declares or pays a dividend
or any other distribution on its Common Stock payable in Common Stock, cash or other securities, or subdivides the outstanding Common
Stock into a greater amount of Common Stock, then upon exercise of this warrant, for each Share acquired, Holder shall receive, without
cost to Holder, the total number and kind of securities, cash or other property to which Holder would have been entitled had Holder owned
the Shares of record as of the date the dividend, distribution or subdivision occurred (subject to further adjustment in the event the
rights of any such securities or property are subsequently amended to increase the number of shares of Common
Stock issuable thereunder or to lower the exercise or conversion price thereof).

 

2.2             Reclassification,
Exchange or Substitution. Upon any reclassification, exchange, consolidation,
substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion
of this warrant, Holder shall be entitled to receive, upon exercise or conversion of this warrant, the number and kind of securities
and property that Holder would have received for the Shares if this warrant had been exercised in full immediately before such reclassification,
exchange, consolidation, substitution, or other event (subject to further adjustment in the event the rights of any such securities or
property are subsequently amended to increase the number of shares of Common Stock issuable thereunder or
to lower the exercise or conversion price thereof). The Company or its successor shall promptly issue to Holder a new warrant
for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may be
practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to
the number of securities or property issuable upon exercise of the new warrant. The provisions of this Section 2.2 shall similarly apply
to successive reclassifications, exchanges, substitutions, or other events.

 

    3

     

    

 

2.3             Adjustments
for Combinations, Etc. If the outstanding Shares are combined or
consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased.
If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a greater number of shares, the Warrant
Price shall be proportionately decreased.

 

2.4             Certificate
as to Adjustments. Upon each adjustment of the Warrant Price, the
Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting
forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate
setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price.

 

2.5             Fractional
Shares. No fractional Shares shall be issuable upon exercise or conversion
of the warrant, and the Number of Shares to be issued shall be rounded up to the nearest whole Share.

 

ARTICLE
3

REPRESENTATIONS AND COVENANTS OF THE COMPANY AND HOLDER

 

3.1             Representations
and Warranties. The Company hereby represents and warrants to the
Holder that all Shares which may be issued upon the exercise of the purchase right represented by this warrant shall, upon issuance,
be duly authorized, validly issued, fully paid and nonassessable, without violation of any preemptive right or similar rights, and free
of any liens, taxes, and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities
laws. The Company will pay all expenses in connection with, and all taxes and other governmental charges that may be imposed with respect
to, the issuance or delivery of Shares upon exercise (or conversion) of this warrant; provided, that the Company shall not be required
to pay any tax or governmental charge that may be imposed with respect to any applicable withholding or the issuance or delivery of the
Shares to any Person other than the Holder, and no such issuance or delivery shall be made unless and until the Person requesting such
issuance has paid to the Company the amount of any such tax, or has established to the satisfaction of the Company that such tax has
been paid.

 

3.2             Notice
of Certain Events. The Company shall provide Holder with not less
than 10 days prior written notice of, including a description of the material facts surrounding, any of the following events: (a) declaration
of any dividend or distribution upon its Common Stock, whether in cash, property, stock, or other securities and whether or not a regular
cash dividend; (b) offering for subscription pro rata to the holders of any class or series of its stock any additional shares of stock
of any class or series or other rights; (c) effecting any reclassification or recapitalization of Common Stock; or (d) the merger or
consolidation with or into any other corporation, or sale, lease, license, or conveyance of all or substantially all of its assets, or
liquidation, dissolution or winding up.

 

    4

     

    

 

3.3             Registration
Under Securities Act of 1933, as amended. The Company agrees that
the Shares shall be “Registrable Securities” and Holder shall be an “Investor” and a “Holder” under
the Investors’ Rights Agreement upon Holder’s due execution and delivery to the Company of a Joinder in substantially the
form of Appendix 2, and the Company will use its best efforts to cause the Shares into which this warrant is exercised
(or converted), immediately upon such exercise (or conversion), to be listed on any domestic securities exchange upon which shares of
Common Stock or other securities constituting Shares are listed at the time of such exercise (or conversion).

 

3.4             Holder
Investment Representations. Holder makes the following representations
to the Company in connection with the issuance of this warrant and the Shares (collectively, the “Securities”):

 

(a)            The
Holder is aware of the Company’s business affairs and financial condition, and has acquired sufficient information about the Company
to reach an informed and knowledgeable decision to acquire the Securities. The undersigned is purchasing the Securities for its own account
for investment purposes only, not as a nominee or agent, and not with a view towards, or for resale in connection with, any “distribution”
thereof for purposes of the Securities Act of 1933, as amended (the “Securities Act”). The undersigned has
such knowledge and experience in financial business matters and the undersigned is capable of evaluating the merits and risks of the
purchase of the Securities and of protecting its interests in connection therewith.

 

(b)            The
Holder understands that the Securities have not been registered under the Securities Act in reliance upon a specific exemption therefrom,
which exemption depends upon, among other things, the bona fide nature of the undersigned’s investment intent as expressed herein.

 

(c)            The
Holder further understands that the Securities must be held indefinitely, and the undersigned must therefore bear the economic risk therewith,
unless the Securities are subsequently registered under the Securities Act or unless an exemption from registration is otherwise available.
In addition, the undersigned understands that the certificate evidencing the Securities will be imprinted with a legend which prohibits
the transfer of the Securities unless they are registered or such registration is not required. Holder is aware of the provisions of
Rule 144 promulgated under the Act.

 

(d)            The
Holder is familiar with the provisions of Rule 144, promulgated pursuant to the Securities Act, which, in substance, permits limited
public resale of “restricted securities” acquired, directly or indirectly, from the issuer thereof, in a non-public offering
subject to the satisfaction of certain conditions.

 

(e)            The
Holder further understands that in the event that all of the applicable requirements of Rule 144 are not satisfied, registration under
the Securities Act, compliance with Regulation A, or some other registration exemption will be required.

 

(f)             The
Holder is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.

 

    5

     

    

 

3.5             “Market
Stand Off” Agreement. The Holder agrees that the Shares shall be subject to the Market Standoff provisions in Section
2.11 of Investors’ Rights Agreement.

 

3.6             No
Voting Rights. Holder, as
a Holder of this warrant, will not have any voting rights until the exercise of this warrant.

 

3.7             Reservation
of Shares. During the period between the Issue Date and the Expiration,
the Company shall at all times reserve and keep available out of its authorized but unissued Common Stock or other securities constituting
Shares, solely for the purpose of issuance upon the exercise of this warrant, the maximum number of Shares issuable upon the exercise
of this warrant, and the par value per Share shall at all times be less than or equal to the applicable Warrant Price. The Company shall
not increase the par value of any Shares receivable upon the exercise of this warrant above the Warrant Price then in effect, and shall
take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
shares of Common Stock upon the exercise of this warrant.

 

ARTICLE
4

MISCELLANEOUS

 

4.1             Term:
Exercise Upon Expiration. This warrant is exercisable in whole or
in part, at any time and from time to time on or before the Expiration Date set forth above. If this warrant has not been exercised prior
to the Expiration Date, this warrant shall be deemed to have been automatically exercised on the Expiration Date by “cashless”
conversion pursuant to Section 1.2.

 

4.2             Legends.
This warrant shall be imprinted with a legend in substantially the following form as well as any additional legends that the Company
and Holder mutually agree upon with respect to such Shares:

 

THE
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO HOLDER DATED
FEBRUARY __, 2021, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR,
IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT
FROM SUCH REGISTRATION.

 

    6

     

    

 

4.3             Compliance
with Securities Laws on Transfer. This warrant and the Shares issued
upon exercise of this warrant may not be transferred or assigned in whole or in part except in compliance with applicable federal and
state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation
letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require
Holder to provide an opinion of counsel if the transfer is to any affiliate of Holder, provided that any such transferee is an “accredited
investor” as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of
counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. This warrant and the rights evidenced
hereby shall be binding upon and shall inure to the benefit of the parties hereto and the successors of the Company and the successors
and assigns of the Holder. Subject to the foregoing, such successors and/or assigns of the Holder shall be deemed to be a Holder for
all purposes hereunder. In the case of a transfer of the warrant, upon surrender and delivery by Holder, the Company shall execute and
deliver a new warrant or warrants in the name of the assignee or assignees and in the denominations specified in any instrument of assignment
provided to the Company by the assignor, and shall issue to the assignor a new warrant evidencing the portion of this warrant, if any,
not so assigned and this warrant shall promptly be cancelled.

 

4.4             Notices.
All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and effective when given
personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the
Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time. All notices to the Holder shall
be addressed as provided in the Investors’ Rights Agreement.

 

4.5             Amendments.
This warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party
against which enforcement of such change, waiver, discharge or termination is sought.

 

4.6             Attorneys’
Fees. In the event of any dispute between the parties concerning
the terms and provisions of this warrant, the party prevailing in such dispute shall be entitled to collect from the other party all
costs incurred in such dispute, including reasonable attorneys’ fees.

 

4.7             Governing
Law. This warrant shall be governed by and construed in accordance
with the laws of the State of Delaware, without giving effect to its principles regarding conflicts of law.

 

4.8             Warrant
Register. The Company shall keep and properly maintain at its principal
executive offices books for the registration of the warrant and any transfers thereof. The Company may deem and treat the person or entity
in whose name the warrant is registered on such register as the Holder thereof for all purposes, and the Company shall not be affected
by any notice to the contrary, except any assignment, division, combination or other transfer of the warrant effected in accordance with
the provisions of this warrant.

 

4.9             Cumulative
Remedies. The rights and remedies provided in this warrant are cumulative
and are not exclusive of, and are in addition to and not in substitution for, any other rights or remedies available at law, in equity
or otherwise.

 

    7

     

    

 

4.10           Equitable
Relief. Each of the Company and the Holder acknowledges that a breach
or threatened breach by such party of any of its obligations under this warrant would give rise to irreparable harm to the other party
hereto for which monetary damages would not be an adequate remedy and hereby agrees that in the event of a breach or a threatened breach
by such party of any such obligations, the other party hereto shall, in addition to any and all other rights and remedies that may be
available to it in respect of such breach, be entitled to equitable relief, including a restraining order, an injunction, specific performance
and any other relief that may be available from a court of competent jurisdiction.

 

4.11           Entire
Agreement. This warrant, together with the Investors’ Rights
Agreement, the Voting Agreement and that certain Stock Purchase Agreement dated February __, 2021 (the “Purchase Agreement”),
constitutes the sole and entire agreement of the parties to this warrant with respect to the subject matter contained herein, and supersedes
all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event
of any inconsistency between the statements in the body of this warrant, the Investors’ Rights Agreement, the Voting Agreement
and the Purchase Agreement, the statements in the body of this warrant shall control.

 

[Signature
Page Follows]

 

    8

     

    

 

IN
WITNESS WHEREOF, the undersigned has executed this Warrant to Purchase Common Stock as of the date set forth above.

 

	 	Sera
    Prognostics, Inc.
	 	 
	 	By:	                  
	 	 
	 	Name:
    	Gregory
    C. Critchfield, M.D., MS
	 	 
	 	Title:	President
    and Chief Executive Officer

 

     

     

    

 

APPENDIX
1

 

NOTICE
OF EXERCISE

 

1.       The
undersigned hereby elects to purchase ______________ shares of Common Stock, $0.0001 par value per share of SERA PROGNOSTICS, INC. pursuant
to the terms of the attached warrant, and tenders herewith payment of the purchase price of such shares in full.

 

1.       The
undersigned hereby elects to convert the attached warrant into shares in the manner specified in the warrant. This conversion is exercised
with respect to _____________ of the shares covered by the warrant.

 

[Strike
paragraph that does not apply.]

 

2.       Please
issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified below:

 

	 	 
	(Holder’s
    Name)	 
	 	 
	 	 
	(Address)	 

 

3.       The
undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a
view toward the resale or distribution thereof except in compliance with applicable securities laws.

 

Holder
or Registered Assignee

 

	 	 
	(Signature)	 
	 	 
	 	 
	(Date)	 

 

     

     

    

 

APPENDIX
2

 

JOINDER

 

DATE:                                    

 

The
undersigned hereby agrees, effective as of the date hereof, (i) to become a party to that certain Fourth Amended and Restated Investors’
Rights Agreement (the “Investors’ Rights Agreement”) dated as of February __, 2021, as amended from time to time, by
and among Sera Prognostics, Inc. and the other parties thereto and for all purposes of the Investors’ Rights Agreement, the undersigned
shall be included within the terms “Investor” and “Holder” as defined in the Investors’ Rights Agreement,
and the undersigned agrees to be bound by the terms and conditions of the Investors’ Rights Agreement as an Investor and Holder
thereunder, and (ii) to become a party to that certain Third Amended and Restated Voting Agreement (the “Voting Agreement”)
dated as of February __, 2021, as amended from time to time, by and among Sera Prognostics, Inc. and the other parties thereto and for
all purposes of the Voting Agreement, the undersigned shall be included within the terms “Investor” and “Stockholder”
as defined in the Voting Agreement, and the undersigned agrees to be bound by the terms and conditions of the Voting Agreement as an
Investor and Stockholder thereunder. The address and facsimile number to which notices may be sent to the undersigned is as follows:

 

	ADDRESS:	 
	 	 
	 	 
	 	 
	Fax:	                         	 

 

	 	By:	                     
	 	Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]